Drugs / Pentavalent-specific T cells (penta-STs)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05471661 | May 2021 → May 2024 | disease related to hematopoietic stem cell transplant, fungal infectious disease, viral infectious disease | George Papanicolaou Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pentavalent-specific T cells (penta-STs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05471661 ↗ |
| Known as | penta-STs | “Pentavalent-specific T cells (penta-STs)” NCT05471661 ↗ |
| Modality | Cell therapy | “donor-derived pentavalent-specific T cells (Penta-STs)” NCT05471661 ↗ |
| Route | Other | “Patients will receive penta-STs in a single infusion.” NCT05471661 ↗ |